CN115427064A - 使用基于脂质结合蛋白的复合物治疗急性病况的方法 - Google Patents

使用基于脂质结合蛋白的复合物治疗急性病况的方法 Download PDF

Info

Publication number
CN115427064A
CN115427064A CN202180028796.XA CN202180028796A CN115427064A CN 115427064 A CN115427064 A CN 115427064A CN 202180028796 A CN202180028796 A CN 202180028796A CN 115427064 A CN115427064 A CN 115427064A
Authority
CN
China
Prior art keywords
lipid
binding protein
based complex
use according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028796.XA
Other languages
English (en)
Chinese (zh)
Inventor
C.图平
C.佩罗特斯
R.巴巴拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abionix Pharmaceuticals
Original Assignee
Abionix Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abionix Pharmaceuticals filed Critical Abionix Pharmaceuticals
Publication of CN115427064A publication Critical patent/CN115427064A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202180028796.XA 2020-04-16 2021-04-15 使用基于脂质结合蛋白的复合物治疗急性病况的方法 Pending CN115427064A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063011055P 2020-04-16 2020-04-16
US63/011,055 2020-04-16
US202063092070P 2020-10-15 2020-10-15
US63/092,070 2020-10-15
US202063121640P 2020-12-04 2020-12-04
US63/121,640 2020-12-04
PCT/IB2021/000283 WO2021209823A1 (en) 2020-04-16 2021-04-15 Methods for treating acute conditions using lipid binding protein- based complexes

Publications (1)

Publication Number Publication Date
CN115427064A true CN115427064A (zh) 2022-12-02

Family

ID=76197484

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028796.XA Pending CN115427064A (zh) 2020-04-16 2021-04-15 使用基于脂质结合蛋白的复合物治疗急性病况的方法

Country Status (10)

Country Link
US (1) US20240033322A1 (https=)
EP (1) EP4135747A1 (https=)
JP (1) JP2023522889A (https=)
KR (1) KR20230004605A (https=)
CN (1) CN115427064A (https=)
AU (1) AU2021256086A1 (https=)
CA (1) CA3177243A1 (https=)
IL (1) IL297336A (https=)
MX (1) MX2022012969A (https=)
WO (1) WO2021209823A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116893215A (zh) * 2023-03-17 2023-10-17 安徽省立医院(中国科学技术大学附属第一医院) 一种用于监测car-t治疗之后crs进程的临床标志物及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297046A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Treatment of kidney disease using cer-001
KR20240018430A (ko) * 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
CA3247588A1 (en) * 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
JP2025519606A (ja) * 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
WO2023237927A2 (en) * 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2024150064A1 (en) * 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953840B2 (en) * 2002-07-30 2005-10-11 Esperion Therapeutics, Inc. Methods of using non-human animal Apolipoprotein A-I protein
WO2018029505A1 (en) * 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
JP3754072B2 (ja) 1994-03-22 2006-03-08 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 摂食抑制ペプチド
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
AU2001257173B2 (en) 2000-04-21 2005-09-22 Amgen Inc. Apo-ai/aii peptide derivatives
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP2343317A1 (en) 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
CA2457840C (en) 2001-08-20 2011-10-11 Zlb Bioplasma Ag Hdl for the treatment of stroke and other ischemic conditions
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
AU2003239489A1 (en) 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
EP2314285B2 (en) 2003-02-14 2019-09-18 Children's Hospital & Research Center at Oakland Lipophilic drug delivery vehicle and methods of use thereof
CN101076541A (zh) 2004-07-16 2007-11-21 塔夫茨大学信托人 载脂蛋白a1模拟物及其用途
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
AU2006282722A1 (en) 2005-08-26 2007-03-01 Cerenis Therapeutics Holdings S.A. Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
WO2008104890A2 (en) 2007-02-28 2008-09-04 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
EA201070517A1 (ru) 2007-10-23 2010-12-30 Дзе Кливленд Клиник Фаундейшн Устойчивый к окислителям аполипопротеин а-1 и пептиды-миметики
LT2939683T (lt) 2009-02-16 2017-03-27 Cerenis Therapeutics Holding Sa Apolipoproteino a-i mimetikai
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
EP2673296B1 (en) * 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
JP6438417B2 (ja) 2013-03-15 2018-12-12 セレニス セラピューティクス ホールディング エスアー スフィンゴミエリンおよびジヒドロスフィンゴミエリンの合成のための方法
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
FR3100715B1 (fr) * 2019-09-12 2023-09-29 Francais Du Sang Ets Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953840B2 (en) * 2002-07-30 2005-10-11 Esperion Therapeutics, Inc. Methods of using non-human animal Apolipoprotein A-I protein
WO2018029505A1 (en) * 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C MICHAEL GIBSON等: "The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction", AMERICAN HEART JOURNAL, vol. 208, 22 November 2018 (2018-11-22) *
CLAUDINE TARDY等: "CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice", ATHEROSCLEROSIS, vol. 232, no. 1, 8 November 2013 (2013-11-08), pages 2, XP028548827, DOI: 10.1016/j.atherosclerosis.2013.10.018 *
D PAJKRT等: "Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia", J. EXP. MED., vol. 184, no. 5, 1 November 1996 (1996-11-01), pages 2 - 3, XP055826216, DOI: 10.1084/jem.184.5.1601 *
EMILY E MORIN等: "HDL in sepsis - risk factor and therapeutic approach", FRONTIERS IN PHARMACOLOGY, vol. 6, 23 October 2015 (2015-10-23), pages 248 *
MCDONALD, MICHELLE C.等: "Reconstituted High-Density Lipoprotein Attenuates Organ Injury and Adhesion Molecule Expression in a Rodent Model of Endotoxic Shock", SHOCK, vol. 20, no. 6, 31 December 2003 (2003-12-31), pages 2 *
YU KATAOKA等: "Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden", CARDIOVASC DIAGN THER., vol. 7, no. 3, 16 June 2017 (2017-06-16) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116893215A (zh) * 2023-03-17 2023-10-17 安徽省立医院(中国科学技术大学附属第一医院) 一种用于监测car-t治疗之后crs进程的临床标志物及其应用

Also Published As

Publication number Publication date
WO2021209823A1 (en) 2021-10-21
AU2021256086A1 (en) 2022-12-15
KR20230004605A (ko) 2023-01-06
CA3177243A1 (en) 2021-10-21
IL297336A (en) 2022-12-01
MX2022012969A (es) 2022-11-09
US20240033322A1 (en) 2024-02-01
JP2023522889A (ja) 2023-06-01
EP4135747A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
CN115427064A (zh) 使用基于脂质结合蛋白的复合物治疗急性病况的方法
JPH10504804A (ja) リポ多糖の中和用組成物
WO2014180229A1 (zh) 仿生重组高密度脂蛋白在制备预防和治疗阿尔茨海默病药物中的应用
EP2760992A1 (en) Use of hemopexin to sequester hemoglobin
US20190224124A1 (en) Methods and Kits for Reducing the Susceptibility of Lipoprotein Particles to Atherogenic Aggregation Induced by Arterial-Wall Enzymes
JP6783652B2 (ja) 抗原特異的免疫原性を低減するための組成物及び方法
EP3692984A1 (en) Annexin-coated particles
WO2024150064A9 (en) Lipid binding protein molecule therapy
US20250255931A1 (en) Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
Yao et al. New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma
JP2020183446A (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
JP2014132832A (ja) 医薬、機能性食品、目的蛋白質の安定化方法、融合蛋白質、核酸、並びに、組換え体
WO2025093929A1 (en) Lipid binding protein molecule therapy
AU2023284357A1 (en) Methods for treating acute conditions using lipid binding protein-based complexes
WO2021237100A1 (en) Methods of targeting extracellular vesicles to lung
US20120157380A1 (en) Pegylated human apoa-1 and process for production thereof
Hardy et al. Could a Non-Cellular Molecular Interactome in the Blood Circulation Influence Pathogens’ Infectivity? Cells 2023, 12, 1699
JP2025518942A (ja) 脂質結合タンパク質に基づく複合体を使用して高炎症状態を処置するための方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination